08:30 | Registration opens | |||
09:00 | Exhibition and Partnering throughout the day | |||
10:00 | General Assembly of the Swiss Biotech Association (by invitation only) | |||
Plenary Session | ||||
11:00 | Welcome Address Domenico Alexakis, CEO, Swiss Biotech Association | |||
11:10 | Key Note I: Transforming Chemistry Rudolf Hanko, CEO, Siegfried AG | |||
11:30 | Key Note II: Innovation@Bayer: Combining Creative Minds With Passion Monika Lessl, Head of Innovation Strategy, Bayer AG | |||
11:50 | Presentation of the Swiss Biotech Report and Panel Discussion Jürg Zürcher, Ernst & Young AG and Member of the Steering Committee | |||
12:30 | Lunch | |||
13.30 | “Investor and Analyst Track” | “Compliance” Presented by KPMG AG | “Emerging Companies” Presented by Bayer | “Impacts on the value chain” Presented by S-GE |
---|---|---|---|---|
| The right balance between Impact of emerging regulations, codes and When does compliance become Compliance program for early research functions Research with Human Biological Material and Data Structuring the insurance portfolio of Life Science Companies Ethics as a business case for |
| Introduction on Value Chains in Biotech New Markets: International Cooperations New Markets – benefits of international R&D cooperation Innovation: Technology Fusion: Processes and Structures: Panel Discussion Moderation: | |
17.00 | Apéro and Wrap-Up of the Day - hosted by Bayer AG | |||
19.00 | End |
Programme Track “Compliance”
Presented by KPMG

Speakers to be defined.
13.30 - 13.45 | Intro – The value of compliance? | Martin Rohrbach |
13.45 - 15.00 | Session 1 Impact of emerging regulations, codes and guidelines on how biotech companies conduct business Regulatory: Sunshine Act, Human Research Law & Nagoya Protocol Key Findings from KPMG’s Global Anti-Bribery and Corruption Survey Clinical research compliance a competitive advantage? | Kathy Tench |
15.30 - 17.00 | Session 2 Ethics as a business case: having the right strategy | Martijn de Kiewit |
Programme Track “Impacts on the value chain”
Presented by S-GE

- Introduction on Value Chains in Biotech
- New Markets International Cooperations
- Innovation Technology Fusion: Biotech meets IT
- Processes and Structures Lean and mean: Biotech structures in Switzerland
- Panel Discussion
Moderation: Monika Jones